These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12384635)

  • 1. Eptifibatide in percutaneous coronary intervention. A review.
    Dery JP; O'Shea JC; Tcheng JE
    Minerva Cardioangiol; 2002 Oct; 50(5):531-46. PubMed ID: 12384635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
    O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
    Tcheng JE; Madan M; O'Shea JC; Cohen EA; Buller CE; Lincoff AM; Popma JJ; Teirstein PS; Kitt MM; Lorenz TJ; Greenberg S; Fost N; Califf RM
    J Interv Cardiol; 2003 Apr; 16(2):97-105. PubMed ID: 12768912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    BioDrugs; 2006; 20(1):63-5. PubMed ID: 16573353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
    Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB
    J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
    Tcheng JE; Lim IH; Srinivasan S; Jozic J; Gibson CM; O'Shea JC; Puma JA; Simon DI
    Circ Cardiovasc Interv; 2009 Feb; 2(1):43-51. PubMed ID: 20031692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Tcheng JE
    Am J Cardiol; 1997 Aug; 80(4A):21B-28B. PubMed ID: 9291242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
    Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
    J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
    O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
    Mayes CE; Kandzari DE; Goldschmidt-Clermont PJ; Phillips HR
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():36E-46E; quiz 47E. PubMed ID: 12668861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
    O'Shea JC; Tcheng JE
    Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.